Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Recent Advances in Management of Renal Cell Carcinoma
share announcement

Recent Advances in Management of Renal Cell Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 10 June 2025 | Viewed by 3136

Special Issue Editors

Dr. Anand Sharma

E-Mail Website
Guest Editor
Department of Medical Oncology, Mount Vernon Cancer Centre, London HA6 2RN, UK
Interests: kidney cancer; prostate cancer; bladder cancer; chemotherapy; immunotherapy; clinical trials
Prof. Dr. Nikhil Vasdev

E-Mail Website
Guest Editor
1. Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Herts NHS Trust, Stevenage SG1 4AB, UK
2. School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9EU, UK
Interests: robotic surgery; urologic oncology; robotic prostatectomy; bladder cancer surgery
Dr. Prantik Das

E-Mail Website
Guest Editor
School of Medicine, Royal Derby Hospital, University of Nottingham, Uttoxeter Road, Derby DE22 3NE, UK
Interests: prostate cancer; radiation therapy; pineal parenchymal tumors; metastatic prostate cancer; proton therapy; hypofractionated radiotherapy; SABR; brachytherapy

Special Issue Information

Dear Colleagues,

First-line treatments with advanced renal cell carcinoma (aRCC) include immune check-point inhibitors used as dual-type combinations (ipilimumab and nivolumab) or tyrosine kinase inhibitors (nivolumab with cabozantinib, pembrolizumab with axitinib or levantinib, and avelumab with axitinib). Significant progress has been made in treatment of aRCC, and newer combinations are being investigated. Other drugs that inhibit hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF) signaling have demonstrated survival advantage. Tyrosine kinase inhibitors and mTor inhibitors have also shown an ability to inhibit aRCC growth. Key questions to answer in aRCC management include how to combine and sequence different types of therapies, as well as how to integrate new approaches in aRCC management. 

The aim of this Special Issue is to define molecular and cellular targets in treating aRCC, including (1) the genetic basis and/or epigenetic mechanism of RCC; (2) drug resistance; (3) newer imaging modalities in diagnosis; (4) rare types of RCC; (5) newer drugs in aRCC treatment; (6) and real-world studies in aRCC. This Special Issue welcomes both original research articles and reviews.

Dr. Anand Sharma
Prof. Dr. Nikhil Vasdev
Dr. Prantik Das
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • different types of therapies
  • molecular and cellular targets
  • genetic basis
  • epigenetic mechanism
  • drug resistance
  • imaging modalities
  • new drugs
  • real world studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4190 KiB  
Article
Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics
by Zhengyuan Qiu, Dalin Zhang, Fernando Jose Garcia-Marques, Abel Bermudez, Hongjuan Zhao, Donna M. Peehl, Sharon J. Pitteri and James D. Brooks
Cancers 2025, 17(8), 1361; https://doi.org/10.3390/cancers17081361 - 18 Apr 2025
Viewed by 408
Abstract
Background/Objectives: Clear-cell renal cell carcinoma (ccRCC) is a heterogenous disease that can be classified into multiple molecular subtypes with differential prognosis and sensitivities to treatments based on their genomic, transcriptomic, proteomic, and metabolic profiles. Patient-derived xenografts (PDXs) are high-fidelity cancer models because [...] Read more.
Background/Objectives: Clear-cell renal cell carcinoma (ccRCC) is a heterogenous disease that can be classified into multiple molecular subtypes with differential prognosis and sensitivities to treatments based on their genomic, transcriptomic, proteomic, and metabolic profiles. Patient-derived xenografts (PDXs) are high-fidelity cancer models because they maintain similar genotypes and immunohistologic phenotypes to the parental tumors and respond to standard-of-care therapies as expected. However, whether the molecular subtypes identified in ccRCC patient samples are preserved in PDX models is not clear. Our objective is to compare the transcriptional and proteomic profiles of our PDX models to those of ccRCC patients and identify both similarities and distinctions between molecular profiles of PDX subtypes and corresponding ccRCC patient subtypes, so that proper PDX subtypes can be used when investigating the corresponding ccRCC patient subtypes. Methods: To match PDXs to the human ccRCC molecular subtypes, we compared the transcriptomic and proteomic profiles of five ccRCC PDX models established in our lab to those of the human ccRCC molecular subtypes reported by our group, as well as other groups, using hierarchical analysis, Principal Component Analysis (PCA), and Permutation Correlation Analysis. The enrichment of key molecular pathways in PDXs and ccRCC subtypes was determined using Gene Set Enrichment Analysis. Results: We found that each PDX resembles one of the molecular subtypes closely at both transcript and protein levels. In addition, PDXs representing different molecular subtypes show unique metabolic characteristics. Moreover, molecular subtypes of PDXs correlated with ccRCC patient subtypes in key pathway activities implicated in ccRCC progression and therapy resistance. Conclusions: Our results suggest that PDX subtypes should be used when investigating the molecular mechanism of cancer progression and therapy resistance for corresponding ccRCC patient subtypes. This “matching” strategy will greatly facilitate the clinical translation of positive findings into the optimal management of ccRCC patients. Full article
(This article belongs to the Special Issue Recent Advances in Management of Renal Cell Carcinoma)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 2857 KiB  
Review
The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)
by Elena Moreno-Olmedo, Ami Sabharwal, Prantik Das, Nicola Dallas, Daniel Ford, Carla Perna and Philip Camilleri
Cancers 2024, 16(15), 2678; https://doi.org/10.3390/cancers16152678 - 27 Jul 2024
Cited by 1 | Viewed by 2038
Abstract
Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, [...] Read more.
Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease. Full article
(This article belongs to the Special Issue Recent Advances in Management of Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop